VTv Therapeutics
VTv Therapeutics, a pharmaceutical company, focusses on the discovery and development of human therapeutics to fill unmet medical needs.
Launch date
Employees
Market cap
$34.7m
Enterprise valuation
($11m) (Public information from Sep 2024)
Share price
$14.93 VTVT
High Point North Carolina (HQ)
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | <1m | 12.4m | 2.8m | 6.4m | 4.0m | 2.0m | - |
% growth | - | 4173 % | (78 %) | 132 % | (38 %) | (50 %) | - |
EBITDA | (50.6m) | (20.1m) | (20.0m) | (12.1m) | (17.6m) | (24.9m) | (25.9m) |
% EBITDA margin | (17374 %) | (162 %) | (724 %) | (189 %) | (440 %) | (1232 %) | - |
Profit | (16.1m) | (7.9m) | (13.0m) | (8.5m) | (13.0m) | (19.2m) | (20.2m) |
% profit margin | (5548 %) | (64 %) | (472 %) | (133 %) | (324 %) | (950 %) | - |
EV / revenue | 227.1x | 5.4x | 27.0x | 14.5x | 13.5x | 21.1x | - |
EV / EBITDA | -1.3x | -3.3x | -3.7x | -7.7x | -3.1x | -1.7x | -0.6x |
R&D budget | 39.6m | 23.0m | 15.1m | 11.0m | 13.3m | 12.4m | 13.6m |
R&D % of revenue | 13622 % | 185 % | 547 % | 172 % | 333 % | 612 % | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | $2.0m | Post IPO Equity | |
* | N/A | $25.0m | Post IPO Equity |
* | $51.0m | Private Placement VC | |
Total Funding | $51.0m |
Related Content
Recent News about VTv Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.